Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 27, 1997 - Issue 1
83
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Metabolism of amitriptyline with CYP2D6 expressed in a human cell line

, &
Pages 33-47 | Published online: 22 Sep 2008
 

Abstract

1. Expressed human cytochrome P450 enzyme CPY2D6 was used to metabolize amitriptyline (AMI). It was established that CYP2D6 not only catalyzed ring 10- hydroxylation of AMI, but also mediated its N -demethylation to nortriptyline (NT), as well as the formation of 10-hydroxy-NT from NT. When the metabolism of AMI by CYP2D6 was repeated in the presence of quinidine, none ofthe metabolites, 10-hydroxyAMI, NT and 10-hydroxy-NT, was formed. 2. Biochemical parameters ofNT formation from AMI were determined, yielding Km 47 48 1 32 mu M; Vmax 3 95 0 11 nmol h mg protein. The same parameters were calculated for the formation of 10-hydroxy-AMI (E Z-isomers) from AMI, yielding Km 10 70 0 20 mu M; Vmax 8 99 0 47 nmol h mg protein. 3. The formation of 10-hydroxy-NT from AMI proceeded primarily via NT and to a much lesser extent via 10-hydroxy-AMI. 4. Quantitative analyses of AMI and its metabolites were difficult to reproduce when the metabolites were analysed underivatized. Two derivatization procedures, acetylation and trifluoroacetylation, were employed to improve assay reproducibility.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.